Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The study is a multicenter, randomized, 2-period, open-label, two arm, cross-over study to
show the superior effect of a 4 week treatment each with QVA149 versus tiotropium on lung
function. Similarly, this study aims to evaluate patient preference after experiencing both
treatment regimens in patients with a clinical diagnosis of COPD (GOLD 2013) and a moderate
to severe airflow limitation who are symptomatic (defined as CAT score of at least 10) at
screening despite being treated with tiotropium